|
|
|
|
|
|
|
|
At ImmunoSolv we have developed novel Dead-Cert® reagents and services for detection and depletion of non-viable cells to improve cell populations in the laboratory or biomanufacturing facility. |
|
|
| |
|
| |
 |
|
|
|
|
-
- Dead-Cert funding from the Technology Strategy Board
ImmunoSolv have successfully competed for much sought-after funding from the UK
government's Technology Strategy Board to undertake feasibility studies in the Board's
Regenerative Medicine Programme. The grant will be used to fund a project
aimed at improving the bioprocessing of therapeutic cells via dead-cell removal.
- Nexxus Innovation Award
- ImmunoSolv won the 2009 Nexxus East of Scotland Life Science Innovation Award for Dead-Cert® Nanoparticles
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Use Dead-Cert® imab6 to detect dying cells from the earliest stages of apoptosis to the latest stages of necrosis.
- Monoclonal antibody
- No requirement for specialised binding buffers
- High sensitivity viability assessment
- Product information
- See data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
We are also applying our Dead-Cert® technology to:
- Improve production and delivery of therapeutic cells and proteins.
- Develop novel anti-cancer therapeutics targeting the host immune response to dying cells.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
